



## NEWS RELEASE

### **For Further Information Contact:**

Paul Averback  
Nymox Pharmaceutical Corporation  
1-800-93NYMOX  
[www.nymox.com](http://www.nymox.com)

### **For Immediate Release:**

## **Nymox Fexapotide Symposium and Panel Discussion at American Urological Association South Central Sectional Annual Meeting in Naples FL**

HASBROUCK HEIGHTS, NJ (November 27, 2017) Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to report on the Symposium which was held on Fexapotide Triflutate studies at the Annual Meeting of the American Urological Association, South Central Section in Naples, November 27. The abstract from the presentation is available at [info@nymox.com](mailto:info@nymox.com).

The symposium, "Fexapotide Triflutate: A Safe and Effective Injectable for BPH" was chaired by Alan Hay MD, FACS of Salem OR. The other panel members at the Symposium were Mohamed Bidair MD of San Diego CA and James Bailen MD FACS of Louisville KY.

Dr. Hay said, "This office-based injection therapy for BPH/LUTS meets my criteria for a game changer. It is safe, rapid-onset, durable, effective and easy for the patient and doctor to administer."

"Fexapotide can easily be utilized as a simple first line in-office treatment for BPH with excellent long-term benefits and minimal risks," said Dr. Bidair.

"The therapeutic effect of Fexapotide is clearly better than current oral therapies, in addition to the considerable convenience when compared to the need to take oral medications every day. The treatment can be repeated with minimal side effects and the cumulative efficacy is indeed promising for patients," Dr. Bailen added.

Fexapotide has been filed for approval in Europe and the filing was accepted for review in September 2017. Nymox's lead drug Fexapotide has been in development for over 10 years and has been tested by expert clinical trial investigative teams in over 70 distinguished clinical trial centers throughout the US, and has been found after 7 years of prospective placebo controlled double blind studies of treatment of 995 U.S. men with prostate enlargement to not only show clinically meaningful and durable relief of BPH symptoms, but also to show a major reduction in the incidence of prostate cancer, compared to placebo and compared to the known and expected normal incidence of the disease. The same clinical program has also shown in a long-term blinded placebo crossover group study an 82-95% reduction in the number of these patients who required surgery after they received crossover Fexapotide in the trial, as compared to patients who did not receive Fexapotide but instead received crossover conventional approved BPH treatments ( $p < .0001$ ).

At the Symposium detailed clinical data on the Phase 3 clinical trials that have been completed for Fexapotide and that have shown excellent safety and efficacy for the treatment of BPH was presented. Scientific data supporting the safety and efficacy from non-clinical and laboratory testing and analysis was demonstrated. The main presentation was followed by a panel discussion and by an interactive question and answer session with the specialist doctors in attendance.

For more information please contact [info@nymox.com](mailto:info@nymox.com) or [800-936-9669](tel:800-936-9669).

Forward Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor

provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of Fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for Fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox's regulatory filings, Nymox's substantial dependence on Fexapotide, Nymox's commercialization plans and efforts and other matters that could affect the availability or commercial potential of Fexapotide. Nymox undertakes no obligation to update or revise any forward looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox's current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2016, and its Quarterly Reports.